- Home
- BRLT vs NXTC Comparison
BRLT vs NXTC Comparison
Compare BRLT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- NXTC
- Stock Information
- Founded
- BRLT 2005
- NXTC 2015
- Country
- BRLT United States
- NXTC United States
- Employees
- BRLT N/A
- NXTC N/A
- Industry
- BRLT Consumer Specialties
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- NXTC Health Care
- Exchange
- BRLT Nasdaq
- NXTC Nasdaq
- Market Cap
- BRLT 25.2M
- NXTC 23.0M
- IPO Year
- BRLT 2021
- NXTC 2019
- Fundamental
- Price
- BRLT $1.86
- NXTC $0.79
- Analyst Decision
- BRLT Hold
- NXTC Strong Buy
- Analyst Count
- BRLT 4
- NXTC 2
- Target Price
- BRLT $2.67
- NXTC $4.00
- AVG Volume (30 Days)
- BRLT 80.8K
- NXTC 201.3K
- Earning Date
- BRLT 03-13-2025
- NXTC 11-07-2024
- Dividend Yield
- BRLT N/A
- NXTC N/A
- EPS Growth
- BRLT N/A
- NXTC N/A
- EPS
- BRLT 0.03
- NXTC N/A
- Revenue
- BRLT $426,982,000.00
- NXTC N/A
- Revenue This Year
- BRLT N/A
- NXTC N/A
- Revenue Next Year
- BRLT $2.47
- NXTC N/A
- P/E Ratio
- BRLT $67.70
- NXTC N/A
- Revenue Growth
- BRLT N/A
- NXTC N/A
- 52 Week Low
- BRLT $1.52
- NXTC $0.76
- 52 Week High
- BRLT $3.40
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- BRLT 45.79
- NXTC 36.33
- Support Level
- BRLT $1.69
- NXTC $0.76
- Resistance Level
- BRLT $1.98
- NXTC $0.83
- Average True Range (ATR)
- BRLT 0.15
- NXTC 0.07
- MACD
- BRLT -0.03
- NXTC 0.01
- Stochastic Oscillator
- BRLT 32.63
- NXTC 14.87
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.